website open

Published by naoto.matsuda on

Related Posts

News

EVerMed Inc. received investment from Summit Pharmaceuticals International Corporation (SPI)

October 15, 2024 EVerMed Inc. received investment from SPI as the 2nd closing of its seed round.　With this capital increase, EVerMed will accelerate the development of its pipeline. SPI is a provider of high-quality integrated Read more…

News

EVerMed Inc. has raised 280 million yen in the 1st close of its seed round

August 9, 2024 EVerMed Inc. has raised 280 million yen in the 1st close of its seed round EVerMed Inc. has raised a total of 280 million yen through a third-party allotment of new shares Read more…

News

Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells

August 2, 2024 Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells EVerMed Inc. and KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Yutaka Ogihara, hereafter “KYORIN”) today Read more…